首页> 外文OA文献 >Pandemic A/H1N1 2009 Influenza Virus-like Particles Elicited Higher and Broader Immune Responses than the Commercial Panenza Vaccine
【2h】

Pandemic A/H1N1 2009 Influenza Virus-like Particles Elicited Higher and Broader Immune Responses than the Commercial Panenza Vaccine

机译:大流行a / H1N1 2009流感病毒样颗粒比商用panenza疫苗引发更高和更广泛的免疫应答

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objectives: The aim was to construct 2009 pandemic A/H1N1 influenza VLPs (virus-like particles) and compare the immunogenicity and protection efficacy with the commercial Panenza vaccine in BALB/c mouse model. Methods: VLPs derived from influenza A/Hong Kong/01/2009 (H1N1) virus were constructed by Bac-to-Bac baculovirus expression system. VLPs were purified by sucrose density gradient ultracentrifugation and then characterized by Western blotting analysis and transmission electron microscopy. After single dose vaccination with 3 µg of VLPs and equal amount of Panenza vaccine, the immune responses and efficacy of protection induced by VLPs were compared with those elicited by the Panenza vaccine in 6-8 week female BALB/c mice. Key findings: VLPs could induce higher antibody titer as determined by hemagglutinin inhibition and microneutralization assay. Furthermore, we demonstrated that VLPs induced better antibody response to neuraminidase. In addition, VLP vaccinated mice had stronger cell-mediated immune response. As a result, our VLPs conferred 100% protection while the Panenza vaccine only conferred 67% protection. Conclusion: From the results, we concluded that influenza VLPs are highly immunogenic and they are promising to be developed as an alternative strategy to vaccine production in order to control the spread of influenza viruses.
机译:目的:目的是构建2009年大流行的A / H1N1流感VLP(病毒样颗粒),并比较商业Panenza疫苗在BALB / c小鼠模型中的免疫原性和保护效果。方法:通过Bac-to-Bac杆状病毒表达系统构建源自甲型流感/香港/ 01/2009(H1N1)病毒的VLP。通过蔗糖密度梯度超速离心纯化VLP,然后通过蛋白质印迹分析和透射电子显微镜表征。用3 µg VLP和等量的Panenza疫苗进行单剂量疫苗接种后,比较了在6-8周的雌性BALB / c小鼠中,VLP诱导的免疫应答和保护因子与Panenza疫苗引起的免疫应答。关键发现:通过血凝素抑制作用和微中和测定,VLP可以诱导更高的抗体滴度。此外,我们证明了VLP可以诱导对神经氨酸酶的更好的抗体反应。另外,接种VLP的小鼠具有更强的细胞介导的免疫反应。结果,我们的VLP提供了100%的保护,而Panenza疫苗仅提供了67%的保护。结论:根据结果,我们得出结论,流感VLP具有高度的免疫原性,有望将其开发为疫苗生产的替代策略,以控制流感病毒的传播。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号